DIETITIANS could provide outpatient medical gastroenterology clinics for patients with irritable bowel syndrome (IBS). Evidence for this was presented on 3rd October 2021 at the virtual UEG Week by Christian Shaw, Sheffield Teaching Hospital NHS Foundation Trust, UK.

“INGEST the best” was the catchphrase coined at the 29th Annual Meeting of United European Gastroenterology (UEG), hosted in the Austrian city of Vienna, the second congress of this speciality with a fully virtual attendance. Often called the ‘City of Music’ due to the influences of Mozart and Beethoven, UEG were able to orchestrate a sophisticated scientific programme over 3 days from a purpose-built TV studio alongside their global headquarters.

The journey of a patient with CD starts at diagnosis. A crucial step is to identify and capture the illness early in the disease course…

BARIATRIC surgery is a safe and long-term treatment for weight loss; however, the rapid weight loss it induces is a major risk factor for the formation of cholesterol gallstones. The causal link between weight-loss and gallstone formation is not fully understood, but an important factor is the consequential imbalance in biliary lipids. Cholecystectomy at the time of bariatric surgery is the current standard treatment for gallstones, the evidence for the use of ursodeoxycholic acid (UDCA) prophylaxis is still under debate. Research led by Sylke Haal, Amsterdam UMC, University of Amsterdam, the Netherlands, was conducted to provide evidence for whether UDCA reduces the occurrence of gallstone disease after bariatric surgery.

RECENT breakthrough research was shared and debated on Day 2 of the United European Gastroenterology (UEG) Week Virtual Congress 2021 in the symposium session discussing the progress towards, and barriers to, the elimination of chronic viral hepatitis (HCV). The session featured experts in the field, including Sabela Lens, Division of Infection and Immunity, University College London, UK, and Jean-Michel Pawlotsky, National Reference Centre for Viral Hepatitis B, C and Delta, Department of Virology & INSERM U955, Henri Mondor Hospital, University of Paris-Est Créteil, France, who came together to share knowledge, challenge findings, and contribute to the fundamental goal of HCV elimination. The symposium looked at all aspects of eliminating HCV, from profiling the disease in the clinic to large-scale epidemiological characteristics of HCV within global populations.

President, Drossman Center for the Education and Practice of Biopsychosocial Care, DrossmanCare; Drossman Gastroenterology, DrossmanCare; President, Drossman Consulting; Professor Emeritus of Medicine and Psychiatry, University of North Carolina (UNC) School of Medicine; President Emeritus and Chief of Operations, Rome Foundation; Former Co-director, UNC Center for Functional GI and Motility Disorders, North Carolina, USA

OESOPHAGEAL cancer (OAC) is the seventh most common cancer in the world. Patients with this cancer are commonly treated with neoadjuvant chemotherapy, radiotherapy, or surgery. Unfortunately, over half of tumours are resistant to neoadjuvant therapy and survival rates are poor. A novel study, shared at the UEG Week Virtual, aimed to understand the genetic and transcriptomic changes in OAC.

Mary Ellen Sanders introduced ‘biotics’ as a family of four microbiome-targeted substances: probiotics, prebiotics, synbiotics, and postbiotics. Each type of biotic has the potential to impact the resident microbes of a host, which have diverse physiological functions, including promotion of fat storage and angiogenesis, immune development, synthesis of vitamins and amino acids, drug metabolism, modification of the nervous system, breakdown of food, resistance to pathogens, protection against epithelial injury, and modulation of bone-mass density.